FDA cleared the Report Studio from Beacon Biosignals, Inc. on Aug 25, 2026 under K261747, a traditional 510(k). The device falls under product code OLV, Standard Polysomnograph With Electroencephalograph, regulated at 21 CFR 882.1400 as a Class 2 device. The review panel was Neurology.

FDA logged the submission as received on May 27, 2026. The decision came 90 days later, inside the 90 FDA-day goal for a 510(k).

This is the only decision on file for Beacon Biosignals, Inc. in the last 12 months of the tracker.